arrow_drop_up arrow_drop_down

Investors

Investors

Corporate Profile

CancerMeds’ service & product development programs generally target pharmaceutical & biotech management teams, and the Company seeks to simultaneously develop, with partners, diagnostic & management tools intended to get the most out of cancer medication. Through these collaborations, CancerMed has the flexibility to generate the most appropriate strategy for each program, and the expertise to gain support global commercialization that will parallel CancerMeds’ commercialization paths. CancerMed believes this reverse-engineered patient-driven approach of cancer medication success, inclusive its Hit Hard, Early, and Short adverse event approach - represents the future of cancer therapy.

Investor Inquiries

Dr. Christine Boers-Doets

+31-6-24790618

christine@cancer-med.com